SCHEMBL2000160

SCHEMBL2000160

COc1ccc(C(=O)N2CCSc3ccc(C(=O)NC4CCCC4)cc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ CNR1 P21554 1/20 0.53
▸ CNR2 P34972 1/20 0.53
▸ GFER P55789 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ TP53 P04637 3/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.52
▸ HPGD P15428 1/20 0.52
▸ CASP1 P29466 1/20 0.52
▸ ALOX15 P16050 1/20 0.51
▸ MAPT P10636 4/20 0.50
▸ USP2 O75604 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ EPHX2 P34913 1/20 0.49
▸ POLB P06746 2/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2003675 0.89 ALDH1A1 (0.56) NPC1RAB9ACNR1CNR2ALDH1A1
SCHEMBL2001152 0.88 CNR1 (0.56) NPC1RAB9ACNR1CNR2ALDH1A1
SCHEMBL2003775 0.87 CNR1 (0.69) NPC1RAB9ACNR1CNR2ALDH1A1
SCHEMBL2000108 0.87 CNR2 (0.56) NPC1RAB9ACNR1CNR2ALDH1A1
SCHEMBL1994848 0.85 RAB9A (0.58) NPC1RAB9AGFERALDH1A1TP53
SCHEMBL1995856 0.84 CNR2 (0.59) NPC1CNR1CNR2ALDH1A1TP53
SCHEMBL2005128 0.82 RAB9A (0.57) NPC1RAB9AGFERALDH1A1TP53
SCHEMBL1999061 0.81 ALDH1A1 (0.61) NPC1RAB9ACNR1CNR2ALDH1A1
SCHEMBL1996879 0.81 GFER (0.58) NPC1RAB9AGFERALDH1A1TP53
SCHEMBL2002931 0.80 GFER (0.59) NPC1RAB9AGFERTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 — — US claimed
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 — — US disclosed
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 — — US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 — — US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 — — US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 — — US disclosed
WO-2009035997-A2 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CNR1, CNR2, TRPV1 NPC1 458/4885RAB9A 1428/4885CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback